CAR-T R&D and Companion Monitoring Solution - GeneRulor | Gene Editing & CGT Safety Assessment Service Provider

English

Location：

CAR-T R&D and Companion Monitoring Solution

1. Industry Background & Regulatory Requirements

CAR-T (Chimeric Antigen Receptor T-cell) cell therapy, as a breakthrough cancer immunotherapy, has demonstrated remarkable efficacy in the treatment of hematologic malignancies. However, CAR-T therapy continues to face challenges including individual variability in treatment response, high relapse rates, and serious adverse events (CRS, ICANS).

In March 2022, the FDA issued the draft guidance Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products, requiring full-process monitoring of CAR-T products, including preclinical testing, manufacturing controls (CMC), and post-infusion monitoring for up to 15 years. The 2022 guidelines of the Chinese Society of Clinical Oncology (CSCO) also emphasize the importance of pre-treatment immune status assessment and long-term post-treatment follow-up.

With the rapid development of single-cell sequencing technologies, regulatory authorities and the scientific community are placing increasing emphasis on immune monitoring at the single-cell level. Single-cell technologies can reveal CAR-T cell heterogeneity, functional states, and evolutionary trajectories at unprecedented resolution, providing powerful tools for understanding treatment failure mechanisms, optimizing product design, and predicting treatment response. Multiple studies published in leading journals have confirmed that single-cell analysis can identify specific CAR-T subpopulations and functional features associated with durable responses, providing new biomarkers for precision medicine.

The companion monitoring emphasized by global regulatory agencies encompasses: pre-treatment assessment (T cell clonality, immune function diversity, tumor burden baseline), post-treatment monitoring (CAR-T expansion kinetics, persistence, immune reconstitution), efficacy evaluation (MRD tracking, relapse prediction), safety monitoring (adverse event early warning, infection risk), and in-depth single-cell level analysis (investigational items). These measures facilitate optimization of CAR-T product development, provide a basis for clinical decision-making, improve treatment success rates, and reduce the risk of adverse events.

2. Industry Pain Points

Stage	Key Pain Points
R&D Stage	Insufficient pre-treatment assessment: Lack of standardized patient selection criteria; difficulty predicting which patients will respond optimally to CAR-T therapy. Conventional bulk detection methods cannot reveal T cell heterogeneity and functional states, leading to relatively high treatment failure rates. Lack of effective efficacy predictors: Difficulty accurately assessing CAR-T cell expansion potential and persistence before treatment, affecting product optimization and clinical protocol design. Single-cell level functional characterization can identify key subpopulations associated with treatment response. Difficulty selecting detection technologies: The variety of immune monitoring technologies on the market (bulk sequencing, flow cytometry, single-cell sequencing, etc.) lacks systematic comparative guidance, making it hard for companies to balance cost and information depth.
Clinical Application Stage	Non-systematic post-treatment monitoring: Lack of standardized processes for post-infusion CAR-T cell persistence and expansion kinetics monitoring; immune reconstitution assessment is incomplete, making it difficult to detect immune-related complications in a timely manner. Incomplete immune reconstitution assessment: Bulk methods can only observe the overall recovery of immune cell counts; they cannot assess the quality of functional immune reconstitution at the single-cell level, making it difficult to identify immune-related complications promptly. Insufficient MRD detection sensitivity: Conventional detection methods (e.g., flow cytometry) have limited sensitivity (10⁻⁴), preventing accurate assessment of minimal residual disease in patients achieving deep remission and affecting relapse prediction. High cost of multi-vendor coordination: Pre-treatment screening, intra-treatment monitoring, and post-treatment follow-up typically require multiple vendors; inconsistent data standards, difficult result interpretation, and complex project management.
Regulatory Compliance Stage	Missing long-term follow-up data: The FDA requires CAR-T products to undergo safety monitoring for up to 15 years; most companies lack a complete long-term follow-up data collection and management system. Complex assay method validation: Regulatory agencies require adequate validation of detection methods (accuracy, precision, sensitivity, specificity, etc.); standardization and validation of single-cell technologies are still evolving, and companies often lack standardized validation workflows and QC systems. High data traceability requirements: The full process from sample collection, testing, and analysis to report generation must comply with GCP/GLP specifications; data management and quality assurance system development are challenging.

3. End-to-End Companion Monitoring Solution

To address the above challenges, we have integrated cutting-edge genomics detection technologies and bioinformatics capabilities—combining conventional bulk sequencing with advanced single-cell sequencing technologies—to build a comprehensive companion monitoring solution covering the full CAR-T product workflow from 'pre-treatment assessment' to 'long-term post-treatment monitoring.' The solution is provided in a modular format, enabling either implementation as a complete systematic program or flexible combination based on client-specific needs.

3.1 Overall Technical Workflow

Our technical roadmap follows the principle of 'precise pre-treatment selection, systematic post-treatment monitoring,' employing a multi-level technology platform (bulk sequencing, single-cell sequencing, solution-phase hybrid capture) with multi-dimensional, multi-time-point assessments to comprehensively evaluate the safety and efficacy of CAR-T therapy.

3.2 Core Service Module Details

Module 1: Pre-Treatment T Cell Clonality Analysis

TCR (T Cell Receptor) repertoire sequencing performed before CAR-T therapy aims to establish a 'baseline profile' of the patient's T cell clonal composition. Since CAR-T cells are autologous or allogeneic T cells that have undergone ex vivo expansion and genetic engineering, understanding pre-treatment T cell clonal diversity and predominant clonotypes is critical for subsequent evaluation of CAR-T cell expansion, persistence, and for distinguishing endogenous T cells from CAR-T cells.

Test Item	Technology Option	Detection Principle	Detection Content
T Cell Receptor Repertoire High-Throughput Sequencing (TCR-seq)	Standard Option: Bulk TCR Sequencing Platform: High-throughput sequencing + UMI technology	DNA/RNA is extracted from the bulk sample; high-throughput sequencing analyzes the TCR sequences of all T cells to obtain clonal composition and frequency distribution.	T cell clonal diversity index Clonal frequency distribution Degree of clonal expansion CDR3 sequences of major clones V/J gene usage frequency
	Advanced Option: Single-Cell TCR Sequencing Platform: 10x Genomics 5' VDJ	TCR sequences of individual T cells are sequenced at the single-cell level; cell phenotype and gene expression information are simultaneously obtained, enabling precise tracking of each clone's characteristics.	All content of the standard option Single-cell clone-phenotype linkage CD4/CD8 typing per clone Clone-specific gene expression High-resolution analysis of rare clones

Module 2: Pre-Treatment Comprehensive Immune Function Assessment

Evaluates the patient's pre-treatment immune status, including T cell and B cell clonal diversity, immune cell subset distribution, and functional state. Clinical value includes: patient selection (identifying patients with good immune function most likely to benefit from CAR-T therapy); efficacy prediction (patients with higher immune diversity typically respond better); source material quality assessment (for autologous CAR-T, evaluating quality of collected T cells); and establishing a baseline for post-treatment immune reconstitution monitoring.

Test Item	Technology Option	Detection Principle	Detection Content
Immune Repertoire Analysis	Standard Option: Bulk sequencing + Flow cytometry Platform: TCR/BCR high-throughput sequencing; Multi-parameter flow cytometry	Bulk sequencing analyzes the overall TCR/BCR repertoire; flow cytometry detects immune cell subsets.	TCR/BCR clonal diversity Clonal expansion analysis T cell subset proportions Lymphocyte counts Composite immune diversity score
Immune Repertoire Analysis	Advanced Option: Single-cell multi-omics analysis Platform: Single-cell TCR/BCR sequencing; Single-cell transcriptome sequencing (scRNA-seq + VDJ)	At single-cell resolution, TCR/BCR sequences, cell phenotype, and whole-transcriptome expression profiles are simultaneously obtained, precisely assessing the functional state and differentiation trajectory of each clone.	All content of the standard option Single-cell clone-phenotype-function trivariate analysis Fine cell subset typing (20+ subsets) Clone-specific functional gene expression T cell differentiation trajectory analysis Rare functional subset identification Inter-clonal heterogeneity analysis

Module 3: Pre-Treatment Tumor Clone Identification

This module aims to precisely identify tumor-specific clones in the patient prior to treatment and establish a 'molecular fingerprint' of the tumor. The identified dominant clones serve as targets for post-treatment minimal residual disease (MRD) monitoring and are critical for assessing efficacy and predicting relapse.

Tumor Type	Test Item	Detection Principle	Detection Content
Hematologic Malignancies (Lymphoma, Leukemia)	IgH/TCR Gene Rearrangement Sequencing Platform: Solution-phase hybrid capture + High-throughput sequencing + UMI technology	Tumor B cells or T cells carry specific immunoglobulin heavy chain (IgH) or T cell receptor (TCR) gene rearrangements. Solution-phase hybrid capture enriches the VDJ rearrangement region; combined with UMI-based high-throughput sequencing, tumor-specific clonal sequences are precisely identified and quantified.	IgH/TCR rearrangement sequences of tumor clones Tumor clone frequency Clonal diversity Tumor burden quantification Major clone and subclone structure Individualized MRD monitoring target sequences
Solid Tumors	Somatic Mutation Detection Platform: Whole exome sequencing (WES); Large panel targeted sequencing (450–600 genes)	Solid tumors arise through somatic mutations (point mutations, indels) and copy number variations. By sequencing tumor tissue vs. normal tissue, tumor-specific mutations are identified as a 'genetic fingerprint.'	Somatic point mutation list Insertions/deletions (Indels) Copy number variations (CNV) Structural variations (SV), gene fusions Clonal structure 2–4 selected mutations as MRD tracking targets

Module 4: Post-Treatment CAR-T Cell Expansion & Persistence Monitoring

The expansion kinetics and persistence of CAR-T cells after infusion are critical determinants of treatment success. Through TCR repertoire sequencing technology, the fate of CAR-T cells can be precisely tracked at the molecular level, assessing their expansion capacity and long-term survival.

Test Item	Technology Option	Detection Principle	Detection Content
CAR-T Cell Kinetics Monitoring	Standard Option: Bulk TCR Sequencing Platform: TCR sequencing	Bulk TCR sequencing compared against pre-treatment baseline identifies and quantifies frequency changes of CAR-T-specific clones.	CAR-T cell kinetics curve Time-to-peak and peak level Expansion fold-change, half-life Persistence score CAR-T clonal lineage analysis Recovery of endogenous T cells
CAR-T Cell Kinetics Monitoring	Advanced Option: Single-cell TCR sequencing dynamic monitoring Platform: 10x Genomics 5' VDJ + Single-cell transcriptome	Tracks expansion, phenotypic changes, and functional state evolution of each CAR-T clone at the single-cell level; precisely analyzes differentiation trajectories and exhaustion status of CAR-T cells.	All content of the standard option Phenotypic evolution of CAR-T clones Clone-specific exhaustion state analysis CAR-T memory/effector differentiation trajectories Molecular features predictive of persistence Inter-clonal functional heterogeneity

Module 5: Post-Treatment Immune Function Assessment & Immune Reconstitution Monitoring

After CAR-T treatment, the patient's immune system undergoes significant remodeling. Immune reconstitution monitoring is used to: assess recovery of immune cell populations including T cells, B cells, and NK cells; monitor the quality of functional immune reconstitution; predict infection risk; guide prophylactic anti-infective therapy and immunoglobulin replacement therapy; and predict relapse risk and long-term prognosis through immune repertoire characteristics.

Test Item	Technology Option	Detection Principle	Detection Content
Immune Reconstitution Dynamic Monitoring	Standard Option: Bulk sequencing + Flow cytometry + Immunoglobulin quantification Platform: TCR/BCR high-throughput sequencing; Multi-parameter flow cytometry; Immunoglobulin quantification	Bulk sequencing evaluates overall T/B cell repertoire reconstitution; flow cytometry quantifies immune cell subsets; immunoglobulin quantification assesses B cell function.	T/B cell repertoire diversity recovery Absolute lymphocyte count recovery T cell subset recovery B cell and NK cell recovery Immunoglobulin levels Composite immune reconstitution score Infection risk assessment
Immune Reconstitution Dynamic Monitoring	Advanced Option: Single-cell immune reconstitution analysis Platform: Single-cell TCR/BCR sequencing + Single-cell transcriptome	Tracks the immune reconstitution process at the single-cell level, precisely evaluating the differentiation maturity and functional recovery quality of each subset.	All content of the standard option Fine cell subset typing (naïve/CM/EM/TEMRA, etc.) Identification and quantification of newly generated T cells Molecular trajectories of immune reconstitution Functional vs. non-functional cell ratios Diversity analysis of clonal reconstitution Early identification of aberrant subsets

Module 6: Post-Treatment Minimal Residual Disease (MRD) Dynamic Tracking

Based on the tumor-specific clones ('molecular fingerprints') identified before treatment, high-sensitivity minimal residual disease (MRD) monitoring is performed after treatment. This is the 'gold standard' for assessing CAR-T efficacy and predicting relapse.

Tumor Type	Test Item	Detection Principle	Detection Content
Hematologic Malignancies	IgH/TCR MRD Detection Platform: Solution-phase hybrid capture + Ultra-deep sequencing (≥100,000x) + UMI technology	Based on tumor-specific IgH/TCR rearrangement sequences identified pre-treatment, individualized probes are designed. Solution-phase hybrid capture enriches the target region; ultra-deep sequencing precisely quantifies tumor clone frequency.	MRD status (positive/negative) MRD quantification Comparison with pre-treatment tumor burden MRD dynamic change trend curve Relapse risk assessment (very low/low/intermediate/high/very high) Correlation with clinical status
Solid Tumors	Circulating Tumor DNA Detection (ctDNA) Platform: Solution-phase hybrid capture + Ultra-deep sequencing (≥100,000x) + UMI technology	Based on 2–4 tumor-specific mutation sites identified pre-treatment, individualized probes are designed. Cell-free DNA is extracted from peripheral blood plasma; solution-phase hybrid capture enriches mutation regions; ultra-deep sequencing quantifies circulating tumor DNA levels.	ctDNA quantification Dynamic change trend Correlation with clinical response Relapse prediction

4. Service Models

Model	Applicable Scenario	Service Content	Deliverables
Complete Companion Monitoring Package (Recommended)	Clients initiating or conducting CAR-T clinical trials	Standard Monitoring Package: Modules 1–6 covering pre-treatment assessment and full post-treatment monitoring using standard methods Advanced Monitoring Package: Modules 1–6 covering pre-treatment assessment and full post-treatment monitoring using advanced single-cell sequencing methods (high information content, high resolution)	Technical documentation meeting IND/NDA filing requirements
Individual Technical Services	Clients with specific testing needs	Pre-treatment assessment only CAR-T persistence monitoring only MRD monitoring only Any combination of modules	Single or multiple testing data reports

5. Client Value

Dimension	Conventional Approach	GeneRulor Solution
Number of Vendors	3–5 vendors (TCR sequencing, flow cytometry, MRD detection, data analysis, each outsourced separately)	1 vendor
Data Consistency	Multiple platforms; difficult to compare	Multi-level technology platform (bulk + single-cell + hybrid capture): high information depth with unified data standards
Technology Platform	Single technology; limited information	Integrated multi-technology platform covering bulk, single-cell and hybrid capture
Technology Flexibility	Fixed technology solution; no flexibility	Flexible configuration: choose bulk or single-cell based on budget and needs
Information Depth	Bulk methods provide only overall picture; cannot resolve heterogeneity	Single-cell option reveals clonal heterogeneity, functional states, and differentiation trajectories, providing key information for mechanism research and product optimization
Cost	Higher (multiple negotiations, multiple sample shipments)	Optimized (all-inclusive package, single sample collection)

One-stop service: 40–50% shorter project timelines, unified data standards, and simplified project management.

6. Our Advantages

Full-Chain Technology Coverage: One of the few domestic companies simultaneously capable of providing end-to-end services across TCR/BCR sequencing, immune phenotyping, and ultra-sensitive MRD detection—greatly reducing client management and communication costs. One-stop service enables seamless cross-platform data integration.
Rich CAR-T Clinical Experience: Successfully serving multiple leading CAR-T companies and clinical research institutions, with in-depth understanding of IND/NDA filing regulatory requirements and technical challenges; providing professional compliance consulting and clinical decision support.
Multi-Level Technology Platform: Possessing both bulk sequencing and single-cell sequencing capabilities, with flexible selection based on clinical needs and budget:
- Bulk sequencing: Cost-effective; suitable for routine monitoring and large-sample studies
- Single-cell sequencing: High resolution; suitable for mechanistic research and detailed analysis
- Both technologies are complementary, providing all-around immune monitoring from macro to micro perspectives
Flexible Service Models: Supporting both all-inclusive packages and individual services, with customized solutions tailored to each client's specific needs and budget. Dedicated project managers provide end-to-end tracking and 24/7 technical support.

7. References

[1] U.S. Food and Drug Administration. (2022). Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products — Draft Guidance for Industry. Center for Biologics Evaluation and Research.

[2] Chinese Society of Clinical Oncology (CSCO). (2022). Guidelines for the Management of CAR-T Cell Therapy for Hematologic Malignancies and Infection Associated with Immune-Targeted Therapy. People's Medical Publishing House.

[3] Yan N, Wang ZL, Wang XJ, et al. (2024). Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia. Cancer Letters, 598: 217104.

[4] Huang Y, et al. (2022). Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy. Bone Marrow Transplantation. https://www.nature.com/articles/s41409-022-01699-2

[5] Wang X, et al. (2019). Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy. Bone Marrow Transplantation. https://www.nature.com/articles/s41409-019-0625-y

[6] International Council for Harmonisation. (2005). ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology.

WeChat

Sina Weibo

QQ space

Douban

Baidu Post Bar

Follow Us

粤ICP备2024238643号

sitemap

Tel：+86 15336557985

E-Mail：service@generulor.com

Micromessenger

Scan to consult

LIN HUABING

Teams：15022705442@163.com